Atara Biotherapeutics Inc. (NASDAQ:ATRA) CFO John Mcgrath sold 5,000 shares of the company’s stock in a transaction dated Wednesday, October 12th. The stock was sold at an average price of $17.47, for a total transaction of $87,350.00. Following the completion of the transaction, the chief financial officer now owns 96,823 shares in the company, valued at approximately $1,691,497.81. The sale was disclosed in a legal filing with the SEC, which is available through this link.

Atara Biotherapeutics Inc. (NASDAQ:ATRA) opened at 15.75 on Friday. The firm’s market cap is $453.77 million. The stock has a 50 day moving average price of $19.73 and a 200 day moving average price of $20.25. Atara Biotherapeutics Inc. has a 52 week low of $13.31 and a 52 week high of $40.80.

Atara Biotherapeutics (NASDAQ:ATRA) last issued its quarterly earnings data on Monday, August 8th. The company reported ($0.66) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.61) by $0.05. Equities research analysts expect that Atara Biotherapeutics Inc. will post ($2.85) EPS for the current year.

Insider Buying and Selling by Quarter for Atara Biotherapeutics (NASDAQ:ATRA)

A number of equities analysts recently issued reports on the stock. Zacks Investment Research upgraded shares of Atara Biotherapeutics from a “sell” rating to a “hold” rating in a research note on Monday. Goldman Sachs Group Inc. cut shares of Atara Biotherapeutics from a “neutral” rating to a “sell” rating and dropped their price target for the stock from $23.00 to $16.00 in a research note on Thursday, September 15th. Citigroup Inc. upped their price target on shares of Atara Biotherapeutics from $8.00 to $10.00 and gave the stock a “sell” rating in a research note on Friday, August 19th. Jefferies Group reiterated a “buy” rating and issued a $25.00 price target on shares of Atara Biotherapeutics in a research note on Tuesday, August 9th. Finally, JMP Securities restated a “buy” rating on shares of Atara Biotherapeutics in a research note on Saturday, July 9th. Two research analysts have rated the stock with a sell rating, one has given a hold rating and five have issued a buy rating to the company. The company has a consensus rating of “Hold” and a consensus target price of $26.14.

Institutional investors have recently modified their holdings of the company. FMR LLC boosted its position in shares of Atara Biotherapeutics by 29.9% in the second quarter. FMR LLC now owns 3,125,407 shares of the company’s stock valued at $70,353,000 after buying an additional 720,313 shares in the last quarter. Redmile Group LLC boosted its position in shares of Atara Biotherapeutics by 5.9% in the second quarter. Redmile Group LLC now owns 2,408,970 shares of the company’s stock valued at $54,226,000 after buying an additional 133,205 shares in the last quarter. Eagle Asset Management Inc. boosted its position in shares of Atara Biotherapeutics by 0.8% in the third quarter. Eagle Asset Management Inc. now owns 980,673 shares of the company’s stock valued at $20,976,000 after buying an additional 8,081 shares in the last quarter. BlackRock Fund Advisors boosted its position in shares of Atara Biotherapeutics by 18.6% in the second quarter. BlackRock Fund Advisors now owns 913,922 shares of the company’s stock valued at $20,572,000 after buying an additional 143,242 shares in the last quarter. Finally, Bridger Management LLC purchased a new position in shares of Atara Biotherapeutics during the first quarter valued at about $14,072,000. 75.50% of the stock is owned by hedge funds and other institutional investors.

About Atara Biotherapeutics

Atara Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. Its segment is the business of developing and commercializing therapeutics. It has approximately two groups of product candidates, such as allogeneic or third-party derived antigen-specific T-cells, and molecularly targeted biologics.

5 Day Chart for NASDAQ:ATRA

Receive News & Stock Ratings for Atara Biotherapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics Inc. and related stocks with our FREE daily email newsletter.